Nice | Rivaroxaban in Acute Coronary Syndrome (ACS)

27th May 2015 by Louise Hudman

Nice | Rivaroxaban in Acute Coronary Syndrome (ACS)

This new guideline from Nice states that rivaroxaban can now be used after ACS with elevated cardiac enzymes. It should be used either with aspirin, or with aspirin and clopidogrel together.

  • It decreases the combined end points of MI, CVA or deaths from cardiovascular events by 20%.
  • There is a 3 x increased risk of major bleeding, so bleeding risk must be assessed.
  • Use beyond 12m hasn’t been studied, so use beyond that point is for clinical judgement.

It is generally started about a week after the event, so it is likely that we will be starting it, though hopefully it will be advised in the discharge summary.

Join

Join to view the rest of this content, as well as access all the benefits of joining NASGP.

Join

Login

Already a member? Login to view this content.

Login

"I am delighted by the way the NASGP has grown and become such a good support group for locums and other non-principals. I have really appreciated the mailings and enjoyed attending one conference. Please keep up the good work!"

Dr Sarah Steed

Dr Sarah Steed

See the full list of features within our NASGP membership plans

Membership